Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lineage Cell Therapeutics Inc (NY: LCTX ) 0.9053 -0.0147 (-1.60%) Official Closing Price Updated: 8:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Lineage Cell Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel October 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility October 03, 2022 Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. Via Benzinga The Three Best Anti-Aging Stocks to Buy in September September 19, 2022 These three anti-aging stocks could see recovery ahead. ATHX, LCTX, and UBX can make great long-term investments Via InvestorPlace Earnings Scheduled For March 10, 2022 March 10, 2022 Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... Via Benzinga Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed September 07, 2022 According to data from Benzinga Pro, during Q2, Lineage Cell Therapeutics's (AMEX:LCTX) reported sales totaled $4.55 million. Despite a 4.38% increase in earnings, the company posted a loss of $6.78... Via Benzinga Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference August 15, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Recap: Lineage Cell Therapeutics Q2 Earnings August 11, 2022 Lineage Cell Therapeutics (AMEX:LCTX) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Via Benzinga Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update August 11, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 August 04, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug July 08, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 June 14, 2022 Upgrades Via Benzinga Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology June 02, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics: Q1 Earnings Insights May 12, 2022 Lineage Cell Therapeutics (AMEX:LCTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Via Benzinga Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 12, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More May 12, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Earnings Preview: Lineage Cell Therapeutics May 11, 2022 Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 May 05, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration May 03, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More May 02, 2022 Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... Via Benzinga Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022 April 26, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness April 25, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer April 13, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022 April 11, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Insiders Buying These 4 Penny Stocks March 30, 2022 The Nasdaq Composite gained around 60 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... Via Benzinga Insiders Buy Over $1.3M Of 4 Penny Stocks March 28, 2022 The Dow Jones tumbled more than 150 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... Via Benzinga Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 March 24, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss March 21, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics's Return On Capital Employed Insights March 14, 2022 Benzinga Pro data, Lineage Cell Therapeutics (AMEX:LCTX) reported Q4 sales of $1.20 million. Earnings fell to a loss of $29.19 million, resulting in a 272.61% decrease from last... Via Benzinga Lineage Cell Therapeutics: Q4 Earnings Insights March 10, 2022 Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... Via Benzinga RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS March 14, 2022 From Lineage Cell Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.